Determination of FasL Expression (MFI) in Lymphocytic Subsets of B-CLL Patients and Healthy Individuals
| Lymphocytic Subset . | B-CLL Patients . | P . | Healthy Donors . |
|---|---|---|---|
| CD4+ | 4.2 ± .63 | <.009 | 2.1 ± .5 |
| CD8+ | 2.8 ± .29 | >.2 | 2.0 ± .7 |
| CD19+ | 2.4 ± .21 | >.9 | 2.3 ± .1 |
| Lymphocytic Subset . | B-CLL Patients . | P . | Healthy Donors . |
|---|---|---|---|
| CD4+ | 4.2 ± .63 | <.009 | 2.1 ± .5 |
| CD8+ | 2.8 ± .29 | >.2 | 2.0 ± .7 |
| CD19+ | 2.4 ± .21 | >.9 | 2.3 ± .1 |
MFI was determined by immunofluorescence staining and FACS analysis and calculated as the ratio of the MFI achieved with anti FasL MoAb/isotype control Moab. MFI >1.5 was considered positive. Means ± SEM of 30 B-CLL patients and 20 healthy individuals are given.